P1-486: Decreased neuronal activity in APP transgenic mice measured via dendritic protein synthesis

2008 ◽  
Vol 4 ◽  
pp. T362-T362
Author(s):  
Melanie Meyer-Luehmann ◽  
Will Stoothoff ◽  
Tara L. Spires-Jones ◽  
Tomo Kowa ◽  
Mirjam Koker ◽  
...  
2006 ◽  
Vol 9 (4) ◽  
pp. 478-480 ◽  
Author(s):  
Rosalina Fonseca ◽  
U Valentin Nägerl ◽  
Tobias Bonhoeffer

2001 ◽  
Vol 21 (15) ◽  
pp. 5063-5070 ◽  
Author(s):  
Christine M. Eischen ◽  
David Woo ◽  
Martine F. Roussel ◽  
John L. Cleveland

ABSTRACT Enforced Bcl-2 expression inhibits Myc-induced apoptosis and cooperates with Myc in transformation. Here we report that the synergy between Bcl-2 and Myc in transforming hematopoietic cells in fact reflects a Myc-induced pathway that selectively suppresses the expression of the Bcl-XL or Bcl-2 antiapoptotic protein. Myc activation suppresses Bcl-XL RNA and protein levels in cultures of primary myeloid and lymphoid progenitors, and Bcl-XL and Bcl-2 expression is inhibited by Myc in precancerous B cells from Eμ-myc transgenic mice. The suppression of bcl-X RNA levels by Myc requires de novo protein synthesis, indicating that repression is indirect. Importantly, the suppression of Bcl-2 or Bcl-XL by Myc is corrupted during Myc-induced tumorigenesis, as Bcl-2 and/or Bcl-XLlevels are markedly elevated in over one-half of all lymphomas arising in Eμ-myc transgenic mice. Bcl-2 and/or Bcl-XL overexpression did not correlate with loss of ARF or p53 function in tumor cells, indicating that these two apoptotic pathways are inactivated independently. Therefore, the suppression of Bcl-XL or Bcl-2 expression represents a physiological Myc-induced apoptotic pathway that is frequently bypassed during lymphomagenesis.


2010 ◽  
Vol 3 (112) ◽  
pp. ra18-ra18 ◽  
Author(s):  
P. R. Westmark ◽  
C. J. Westmark ◽  
S. Wang ◽  
J. Levenson ◽  
K. J. O'Riordan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document